Clinical Trial Update: Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating doxorubicin-eluting intra-arterial embolization for aggressive desmoid fibromatosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Fibromatoses
• Desmoid Fibromatosis
• Desmoid Neoplasm
• Desmoid Tumor

Drugs mentioned

• Doxorubicin-eluting intra-arterial embolization (doxorubicin)

Snippet

Sponsor: Rabin Medical Center | Conditions: Desmoid, Desmoid Fibromatosis of Skin | Phase 2 | Status: COMPLETED